Drug Repurposing in Cancer Therapy: Approaches and Applications provides comprehensive and updated information from experts in basic science research and clinical practice on how existing drugs can be repurposed for cancer treatment. The book summarizes successful stories that may assist researchers in the field to better design their studies for new repurposing projects. Sections discuss specific topics such as in silico prediction and high throughput screening of repurposed drugs, drug repurposing for overcoming chemoresistance and eradicating cancer stem cells, and clinical investigation on combination of repurposed drug and anticancer therapy.
Cancer researchers, oncologists, pharmacologists and several members of biomedical field who are interested in learning more about the use of existing drugs for different purposes in cancer therapy will find this to be a valuable resource.
- Presents a systematic and up-to-date collection of the research underpinning the various drug repurposing approaches for a quick, but in-depth understanding on current trends in drug repurposing research
- Brings better understanding of the drug repurposing process in a holistic way, combining both basic and clinical sciences
- Encompasses a collection of successful stories of drug repurposing for cancer therapy in different cancer types
2. Successful stories of drug repurposing for cancer therapy in major cancer types
3. Identification of "drug sensitizer by drug repurposing to increase anticancer efficacy of classical cytotoxic drugs, radiotherapy, molecular targeted drugs, or immunotherapy
4. Drug repurposing for eradicating cancer stem cells
5. In silico approaches for identifying repurposed drugs for cancer therapy
6. High-throughput screening strategies for identifying repurposed drugs for cancer therapy
7. System biology approaches for identifying repurposed drugs for cancer therapy and for understanding of mechanisms
8. Clinical trials on combination of repurposed drugs and anticancer therapies
Prof. Kenneth To is currently an Associate Professor in the Chinese University of Hong Kong. He received post-doctoral training at the National Cancer Institute, National Institute of Health, USA, investigating the mechanisms of multidrug resistance and cancer epigenetics. After he became an independent investigator, his research interests focus on the development of novel strategies to overcome drug resistance to classical cytotoxic anticancer drugs as well as molecular targeted cancer therapeutics. He has served as Guest Associate Editor (Frontiers in Oncology & Frontiers in Genetics), Consulting Editor (Pharmacology Research and Perspectives) and Editorial Board Member in 4 other journals in the fields of cancer research and pharmacology. He published more than 100 peer-reviewed articles in highly ranked scientific journals in cancer biology and pharmacology.
Cho, William C.S.
Dr. William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. His main research interests have been focusing on cancer researches. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of some universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr. Cho has published about 300 peer-reviewed papers (Lancet Oncology, Nature Communications, PNAS, etc.) covering cancer biomarkers, anti-cancer drugs, proteomics, microRNAs, Chinese medicine and over a dozen of books.